GSTM5 and glioblastoma: For instance, PCSK9 (6.3-fold increase), CEL (15.1-fold increase), or GSTM5 (3.9-fold decrease), despite their relatively important deregulation, had only been reported in lung cancer for PCSK9 [23], pancreatic and nasopharyngeal carcinoma for CEL [24, 25], Barret esophagus and glioblastoma for GSTM5 [26, 27].